Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis by Pouya Azar et al.
Azar et al. BMC Infectious Diseases  (2015) 15:193 
DOI 10.1186/s12879-015-0913-0RESEARCH ARTICLE Open AccessDrug use patterns associated with risk of
non-adherence to antiretroviral therapy among
HIV-positive illicit drug users in a Canadian setting:
a longitudinal analysis
Pouya Azar1, Evan Wood1,2, Paul Nguyen1, Maxo Luma1, Julio Montaner1,2, Thomas Kerr1,2 and M-J Milloy1,2*Abstract
Background: Among people living with HIV/AIDS, illicit drug use is a risk for sub-optimal treatment outcomes.
However, few studies have examined the relative contributions of different patterns of drug use on adherence to
antiretroviral therapy (ART). We sought to estimate the effect of different types of illicit drug use on adherence in a
setting of universal free HIV/AIDS treatment and care.
Methods: Using data from ongoing prospective cohorts of HIV-positive illicit drug users linked to comprehensive
pharmacy dispensation records in Vancouver, Canada, we examined factors associated with ≥95% prescription refill
adherence using generalized estimating equations (GEE) logistic regression.
Results: Between 1996 and 2013, 692 ART-exposed individuals were followed for a median of 42.7 months (Interquartile
Range: 29.1–71.7). In multivariable GEE analyses, heroin injection (Adjusted Odds Ratio [AOR] = 0.75, 95% Confidence
Interval [CI]: 0.66–0.85) as well as cocaine injection (AOR = 0.80, 95% CI: 0.72–0.90) were associated with lower likelihoods
of optimal adherence. Methadone maintenance therapy (AOR = 1.88, 95% CI: 1.68–2.11) was associated with a greater
likelihood of adherence.
Conclusions: Periods of heroin and cocaine injection appeared to have the most deleterious impact upon antiretroviral
adherence. The findings point to the need for improved access to treatment for heroin use disorder, particularly methadone,
and highlight the need to identify strategies to support ART adherence among cocaine injectors.
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The development of antiretroviral therapy (ART) has led
to substantial declines in HIV/AIDS-associated morbid-
ity and mortality among many groups in many settings
worldwide [1]. Adherence to ART is the primary factor
determining the degree and durability of optimal re-
sponse to treatment, including achieving non-detectable
levels of plasma HIV RNA. [2]. Studies indicate that up
to 95% adherence is required to achieve maximum viral
load suppression [3]. Suboptimal adherence is associated* Correspondence: uhri-mjsm@cfenet.ubc.ca
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unless otherwise stated.with an increased risk of HIV/AIDS-associated mortality
and morbidity [3] and elevated rates of viral resistance
to treatment [4].
In many studies, active illicit drug use among individ-
uals living with HIV/AIDS is associated with decreased
access to HIV treatment, reduced medication adherence
and increased mortality [5]. Although many studies have
focused on the impact of heroin use on the clinical man-
agement of HIV infection [6,7] fewer studies have exam-
ined the influence of distinct illicit drug use patterns.
Thus, we sought to examine the relative contribution of
different illicit drug use patterns on ART non-adherence
among a group of HIV-positive illicit drug users.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data for these analyses were derived from the Vancouver
Injection Drug Users Study (VIDUS) and AIDS Care Co-
hort to evaluate Exposure to Survival Services (AC-
CESS), two ongoing prospective observational cohorts of
illicit drug users in Vancouver, Canada. Beginning in
1996, persons who had injected illicit drugs other than
cannabinoids in the previous month were recruited into
VIDUS. Since 2005, persons who used illicit drugs and
were HIV-seropositive at baseline or during the study
are subsequently followed in ACCESS. Both cohorts use
identical recruitment and follow-up procedures to allow
for combined analyses.
Described in detail previously [8-10], the cohorts were
populated through snowball sampling and extensive
street outreach in the city’s Downtown Eastside neigh-
bourhood, an area with an open drug market and high
levels of injection drug use, poverty and HIV infection
[11,12]. Participants of these studies were 18 years of age
or older and provided written informed consent. At base-
line and every six-month follow-up interview, participants
answered a standardized interviewer-administered ques-
tionnaire, were examined by a study nurse and provided
blood samples for serologic analysis. Participants are ac-
tively referred to primary care services and drug treatment
programs where available and were provided with a $30
stipend per study visit. A unique feature of these studies is
that the Canadian province of British Columbia delivers
all HIV care including medications at no charge and em-
ploys a system in which every instance of antiretroviral
dispensation and all HIV clinical monitoring is captured
through a centralized registry [8,13,14]. This allows a com-
prehensive retrospective and prospective clinical HIV pro-
file for all participants. Ethics approval has been provided
annually by University of British Columbia/Providence
Health Care Research Ethics Board.
The present analyses considered all HIV-seropositive
participants who had been dispensed at least one day of
antiretroviral therapy (ART) between May 1996 and
May 2013. The primary outcome of interest in this study
was adherence to ART in the six month period prior to
each study interview. As in previous studies [9,15], we
estimated antiretroviral adherence using a validated
measure based on pharmacy refill records provided by
the confidential record linkage with the database of the
Drug Treatment Program. Specifically, adherence was
estimated by calculating the number of days for which
an individual was dispensed ART in the previous six
months over the number of days since they had initiated
ART, capped at 180 days. We dichotomized this measure
as ≥95% vs. <95%. The cut-off threshold of 95% was
chosen as this level has previously been shown to be
closely associated with virological suppression and sur-
vival [15,16].Explanatory variables of interest included socio-
demographic data: age (per 10 years older), gender (fe-
male vs. male), and Caucasian ancestry (yes vs. no).
Variables related to drug use characteristics included: her-
oin injection (yes vs. no), cocaine injection (yes vs. no),
amphetamine injection (e.g., “speed”, “uppers”, crystal
methamphetamine; yes vs. no), crack cocaine smoking
(yes vs. no), and enrollment in methadone maintenance
therapy (yes vs. no). All drug use characteristics defined
above were treated as time-updated based on question-
naire data pertaining to the six month period prior to each
study interview [8,13]. We also included CD4 cell count
(per 100 cells/μL increase) at ART initiation using the last
CD4 cell count observation conducted prior to the first
dispensation of ART. We also included a time-updated
variable measuring the time since the participant initiated
antiretroviral therapy (per year increase), using records
from this setting’s comprehensive antiretroviral dispensary.
As a first step, we visually inspected trends in the propor-
tion of all participants reporting heroin injecting, cocaine
injecting, crack smoking and amphetamine injecting at
each interview period. Next, we visually inspected changes
in median adherence rate at each interview period over
time.
Since serial measures for each subject (i.e., multiple 6-
month observation periods) were available for many par-
ticipants, we estimated the relationships between differ-
ent socio-demographic, drug use and clinical factors and
adherence using generalized estimating equations (GEE)
with a logit-link function. As a first step, we conducted
bivariable GEE analyses to determine which variables were
statistically associated with adherence in unadjusted ana-
lyses. To adjust for potential confounding and identify fac-
tors that were associated with the outcome, all significant
variables in the bivariable analyses were considered in the
full multivariable model. With the drug use patterns being
forced into the model, a backwards model selection pro-
cedure was used to identify the multivariate model with
the best overall fit as indicated by the lowest quasilikeli-
hood under the independence model criterion value. All
statistical analyses were performed using the SAS software
version 9.3 (SAS, Cary, NC). All p-values are two-sided.
Results
During the study period, 692 individuals were included
in these analysis, among whom 213 (30.8%) were female,
the median age at baseline was 42 years (Inter-quartile
Range (IQR): 35–47) and the median follow-up duration
was 42.7 months (IQR: 29.1–71.7). At baseline (Table 1),
338 (48.8%) individuals reported heroin injection in the
previous six months, 388 (56.1%) reported cocaine injec-
tion in the previous six months, 84 (12.1%) reported am-
phetamine injection in the previous six months and 451
(65.2%) reported smoking crack cocaine in the previous
Table 1 Baseline characteristics of 692 HIV-positive illicit drug users stratified by adherence to ART in the previous six
months
Characteristic <95% adherence ≥95% adherence OR1 95% CI2 p value
301 (43.5) n (%) 392 (56.6) n (%)
Age
Median (IQR) 40 (34 – 45) 43 (36 – 48) 1.05 1.02 – 1.06 <0.001
Gender
Male 195 (64.8) 284 (72.6) 1.00
Female 106 (35.2) 107 (27.5) 0.69 0.50 – 0.96 0.027
Caucasian ancestry
No 143 (47.5) 140 (35.8) 1.00
Yes 158 (52.5) 251 (64.2) 1.62 1.19 – 2.20 0.002
Heroin injection3
No 141 (47.0) 211 (54.1) 1.00
Yes 159 (53.0) 179 (45.9) 0.75 0.56 – 1.02 0.064
Cocaine injection3
No 126 (41.9) 178 (45.5) 1.00
Yes 175 (58.1) 213 (54.5) 0.86 0.64 – 1.17 0.336
Amphetamine injection3
No 271 (90.0) 337 (86.2) 1.00
Yes 30 (10.0) 54 (13.8) 1.45 0.90 – 2.33 0.125
Crack cocaine smoking3
No 107 (35.5) 134 (34.2) 1.00
Yes 194 (64.5) 257 (65.7) 1.06 0.77 – 1.45 0.727
MMT3
No 202 (67.1) 210 (53.7) 1.00
Yes 99 (32.9) 181 (46.3) 1.76 1.29 – 2.40 <0.001
Time since ART initiation (per year) 5.1 (2.5 – 8.9) 6.5 (3.1 – 11.4) 0.94 0.91 – 0.97 <0.001
Median (IQR)
CD4+ cells at ART initiation
Median (IQR) 260 (150 – 390) 220 (140 – 360) 1.00 1.00 – 1.00 0.074
1. Odds Ratio; 2. 95% Confidence Interval; 3. Refers to 180 day period prior to the baseline interview.
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view period reporting these drug use patterns are shown
in Figure 1. Figure 2 depicts the median adherence rate
for all participants at each interview period as well as the
lower and upper quartiles. Over the entire study period,
the median adherence rate was 98% (Inter-Quartile Range
[IQR]: 37, 100). Among all observation periods, 3073
(51%) were characterized by ≥95% adherence. Correlation
between the adherence rate and plasma HIV-1 RNA viral
load (log10 transformed) was −0.67; correlation between
the adherence rate and CD4+ cell count was 0.17.
The bivariable and multivariable GEE analyses of ad-
herence to ART are shown in Table 2. In the final multi-
variable model, heroin injection (Adjusted Odds Ratio
[AOR] = 0.76, 95% Confidence Interval [CI]: 0.67–0.85),
cocaine injection (AOR = 0.74, 95% CI: 0.66–0.83), femalesex (AOR = 0.77, 95% CI: 0.68 – 0.87) and CD4 cell count
at ART initiation (AOR = 0.87, 95% CI: 0.83 – 0.92) were
negatively associated with optimal adherence to ART.
Older age (AOR = 1.66, 95% CI: 1.54 – 1.80) and use of
methadone maintenance therapy (AOR = 1.88, 95% CI:
1.68 –2.11) were independently and positively associated
with optimal adherence to ART.
Discussion
In this long-running community-recruited study of illicit
drug users linked to comprehensive HIV clinical records
in a setting of universal free HIV/AIDS treatment and
care, we observed that periods of heroin and cocaine in-
jection were independently and negatively associated
with the likelihood of optimal adherence to ART. We
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Figure 1 Drug use patterns over time; Proportion of all participants reporting heroin injection, cocaine injection, crack cocaine smoking and amphetamine
injection in the previous 180 days at each survey period (plus symbol), with 95% confidence intervals.
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ing and the likelihood of optimal adherence to ART.
Meanwhile, engagement in methadone maintenance
therapy was independently and positively associated with
optimal adherence to ART.
Our finding of strong and independent links between
heroin use, engagement in methadone maintenance and
the likelihood of optimal ART adherence suggests that the
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Figure 2 Antiretroviral adherence patterns over time; Median antiretroviral
each survey period (diamond), with lower and upper quartiles.such as methadone, will likely improve retention in HIV/
AIDS care among opioid-dependent illicit drug users
[17-19]. Improving access to methadone will require
scale-up treatment slots in settings where methadone is
currently available and removal of legal impediments to
this evidence-based opioid treatment modality [20].
In our study, we did not observe a statistical relation-
ship between amphetamine use and adherence to ART.
Crystal methamphetamine use is particularly prevalentSurvey Period
6 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
adherence rate achieved in the last 180 days among all participants at
Table 2 Univariable and multivariable generalized estimating equations analyses of factors associated with ≥ 95%
adherence to antiretroviral therapy among 692 illicit drug users
Characteristic OR1 95% CI2 p AOR3 95% CI2 p
Gender (female vs. male) 0.70 0.56 – 0.88 0.002 0.77 0.68 – 0.87 0.038
Age (per 10 years older) 2.04 1.75 – 2.38 <0.001 1.66 1.54 – 1.80 <0.001
Caucasian (yes vs. no) 1.37 1.12 – 1.69 0.002 1.07 0.95 – 1.19 0.571
Heroin injection (yes vs. no)4 0.67 0.58 – 0.78 <0.001 0.76 0.67 – 0.85 0.002
Cocaine injection (yes vs. no)4 0.73 0.63 – 0.85 <0.001 0.74 0.66 – 0.83 0.001
Amphetamine injection (yes vs. no)4 1.14 0.89 – 1.47 0.305
Crack cocaine smoking (yes vs. no)4 0.95 0.82 – 1.10 0.525
Methadone maintenance therapy (yes vs. no)4 1.74 1.45 – 2.10 <0.001 1.96 1.75 – 2.19 <0.001
Time since ART initiation (per year increase) 1.08 1.06 – 1.11 <0.001 1.02 0.99 – 1.04 0.090
CD4+ cell count at ART initiation (per 100 cells/mL increase) 0.87 0.83 – 0.92 <0.001 0.88 0.85 – 0.90 <0.001
1. Odds Ratio; 2. 95% confidence interval; 3. Adjusted Odds Ratio; 4. Time-updated, refers to the six-month period prior to the interview.
Azar et al. BMC Infectious Diseases  (2015) 15:193 Page 5 of 6among some populations of people living with HIV/
AIDS and persons at risk for HIV, especially men who
have sex with men. [21-23] Numerous studies have
found that, among this population, amphetamine use in
is linked to decreased medication adherence as a result
of binging episodes, and in the long-term, has been asso-
ciated with the development of antiretroviral-resistant
viral strains [23]. In the current study, which contained a
high proportion of individuals reporting periods of poly-
substance use, this association was not observed. This
might reflect the relatively smaller number of individuals
reporting periods of amphetamine injection and with co-
horts of men who have sex with men, which would be
more heterogeneous with respect to drug use. Instead, the
present study observed a strong and independent link be-
tween injection cocaine use and sub-optimal adherence,
underling the urgent need for effective pharmacotherapies
to address stimulant use, especially in the context of HIV
disease.
Although we observed increasing levels of adherence
over time, a substantial proportion of all participants dis-
played sub-optimal adherence to prescribed treatment at
every interview period. Our model indicates that specific
drug use patterns each had different relationships to anti-
retroviral adherence. For example, while periods of heroin
injection were 23% less likely to be characterized by ≥95%
adherence, there was no significant difference between
levels of optimal adherence during periods of amphet-
amine injection. Unfortunately, our model does not offer
specific insights into possible explanations for these diver-
gent results. Thus, future research should investigate the
possible behavioural-, psychologic-, social- and structural-
level barriers and facilitators of adherence for different
groups of illicit drug users in order to optimize substance
abuse treatment and support ART adherence.
There are some limitations to this study to note. Par-
ticipant selection for this observational study was notrandom and the results of this study cannot be general-
ized to the wider population of HIV-positive illicit drug
users. Regarding associations drawn from the results of
the study, there is potential for unmeasured confound-
ing. In an attempt to minimize the impact of confound-
ing on the observed relationships we used multivariable
modelling. Also, we have previously observed that at
least 95% adherence to prescribed ART is strongly asso-
ciated with viral suppression and survival [15,16]. Newer
formulations of ART are more potent and evidence sug-
gests they may deliver comparable rates of viral suppres-
sion at lower adherence thresholds [24,25]. Thus, future
research might consider the effects of illicit drug use on
attaining different adherence thresholds and viral sup-
pression. Finally, we recognize that we are unable to de-
termine the possible temporal relationships between
illicit drug use behaviours and antiretroviral dispensation
patterns within any 180-day observation period.
Conclusions
To conclude, our study utilized data from a long-running
community-recruited prospective cohort of HIV-seropositive
illicit drug users in the setting of free and universal access
to HIV care. Periods of injection heroin use and injection
cocaine use were both independently and negatively asso-
ciated with a lower likelihood of optimal adherence to
ART while engagement in MMT was associated with
higher levels of optimal adherence. Given the importance
of addressing substance use in the community and the
proven success of MMT at reducing the risk of drug-
related harms, our findings support the need to spur ef-
forts to improve access to treatment for problematic
substance use among individuals living with HIV/AIDS.
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